Get the Stockscreener App
6.93
4.41%
-0.32
After Hours:
7.00
0.07
+1.01%
Corvus Pharmaceuticals Inc stock is traded at $6.93, with a volume of 802.83K.
It is down -4.41% in the last 24 hours and up +16.86% over the past month.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
See More
Previous Close:
$7.25
Open:
$7.24
24h Volume:
802.83K
Relative Volume:
1.30
Market Cap:
$516.38M
Revenue:
-
Net Income/Loss:
$-27.03M
P/E Ratio:
-12.37
EPS:
-0.56
Net Cash Flow:
$-23.97M
1W Performance:
-3.62%
1M Performance:
+16.86%
6M Performance:
+141.46%
1Y Performance:
+19.28%
1-Day Range:
$6.78
$7.29
1-Week Range:
$6.39
$7.37
52-Week Range:
$2.54
$10.00
Corvus Pharmaceuticals Inc Stock (CRVS) Company Profile
Name
Corvus Pharmaceuticals Inc
Sector
Industry
Phone
(650) 900-4520
Address
863 MITTEN ROAD, BURLINGAME, CA
Compare CRVS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRVS
Corvus Pharmaceuticals Inc
|
6.93 | 540.23M | 0 | -27.03M | -23.97M | -0.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Corvus Pharmaceuticals Inc Stock (CRVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-02-25 | Initiated | H.C. Wainwright | Buy |
| Aug-18-23 | Initiated | Oppenheimer | Outperform |
| Dec-01-21 | Resumed | Jefferies | Buy |
| May-27-21 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-10-21 | Downgrade | Mizuho | Buy → Neutral |
| Sep-12-19 | Initiated | Mizuho | Buy |
| May-29-19 | Initiated | ROTH Capital | Buy |
| Aug-24-17 | Upgrade | Credit Suisse | Underperform → Neutral |
| May-01-17 | Downgrade | Credit Suisse | Neutral → Underperform |
| Apr-18-16 | Initiated | Credit Suisse | Outperform |
| Apr-18-16 | Initiated | Guggenheim | Buy |
View All
Corvus Pharmaceuticals Inc Stock (CRVS) Latest News
Corvus Pharmaceuticals Inc.’s volatility index tracking explainedShort Setup & Safe Entry Momentum Stock Tips - newser.com
What analysts say about Corvus Pharmaceuticals Inc stockInsider Trading Activity & Free Lightning Fast Capital Gains - earlytimes.in
Weiss Ratings Reaffirms "Sell (D-)" Rating for Corvus Pharmaceuticals (NASDAQ:CRVS) - MarketBeat
Detecting support and resistance levels for Corvus Pharmaceuticals Inc.July 2025 Momentum & Verified Momentum Watchlists - newser.com
Empirical Financial Services LLC d.b.a. Empirical Wealth Management Invests $672,000 in Corvus Pharmaceuticals, Inc. $CRVS - MarketBeat
Has Corvus Pharmaceuticals Inc. formed a bullish divergenceJuly 2025 Reactions & Breakout Confirmation Trade Signals - newser.com
Published on: 2025-10-03 06:35:03 - newser.com
Measuring Corvus Pharmaceuticals Inc.’s beta against major indicesEarnings Miss & Community Verified Trade Signals - newser.com
Chart based exit strategy for Corvus Pharmaceuticals Inc.July 2025 Macro Moves & Advanced Technical Signal Analysis - newser.com
Candlestick signals on Corvus Pharmaceuticals Inc. stock todayWall Street Watch & Daily Stock Trend Watchlist - newser.com
Corvus Pharmaceuticals appoints David Moore to board of directors - Investing.com
Corvus Pharmaceuticals Appoints David Moore To Board Of Directors - TradingView
Novo Nordisk EVP David Moore Joins Corvus Board to Advance ITK Inhibitor Platform and Commercial Strategy - Stock Titan
Published on: 2025-10-01 07:08:07 - newser.com
What drives Corvus Pharmaceuticals Inc stock priceStock Rotation Strategies & Low Risk Capital Appreciation - earlytimes.in
Is Corvus Pharmaceuticals Inc a good long term investmentRisk-Reward Ratio Analysis & Tap Into the Fastest-Growing Companies - Early Times
Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Up 6.1%Should You Buy? - MarketBeat
Are Investors Undervaluing Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) By 37%? - 富途牛牛
While institutions invested in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) benefited from last week's 12% gain, individual investors stood to gain the most - simplywall.st
Is Corvus Pharmaceuticals Inc. trending in predictive chart modelsMarket Growth Report & Growth Oriented Trade Recommendations - newser.com
What candlestick patterns are forming on Corvus Pharmaceuticals Inc.Weekly Profit Report & Free Daily Entry Point Trade Alerts - newser.com
Is Corvus Pharmaceuticals Inc. forming a reversal patternMarket Trend Report & Reliable Intraday Trade Plans - newser.com
How to integrate Corvus Pharmaceuticals Inc. into portfolio analysis toolsJuly 2025 Short Interest & Weekly Breakout Opportunity Watchlist - newser.com
Moving Averages: Is Corvus Pharmaceuticals Inc undervalued by DCF analysis2025 Performance Recap & Risk Controlled Daily Trade Plans - خودرو بانک
Using data models to predict Corvus Pharmaceuticals Inc. stock movement2025 Volatility Report & Safe Capital Growth Stock Tips - newser.com
How to manage a losing position in Corvus Pharmaceuticals Inc.Quarterly Trade Summary & Fast Entry High Yield Tips - newser.com
Will Corvus Pharmaceuticals Inc stock hit new highs in YEAR2025 Growth vs Value & Accurate Technical Buy Alerts - khodrobank.com
Layoff Watch: Is Corvus Pharmaceuticals Inc undervalued by DCF analysisMarket Performance Report & Low Drawdown Investment Ideas - khodrobank.com
Visual analytics tools that track Corvus Pharmaceuticals Inc. performanceQuarterly Trade Report & Daily Market Momentum Tracking - newser.com
Published on: 2025-09-20 03:21:59 - خودرو بانک
Has Corvus Pharmaceuticals Inc. found a price floorPrice Action & Daily Stock Momentum Reports - newser.com
Is Corvus Pharmaceuticals Inc. building a consolidation baseIndex Update & Weekly Breakout Stock Alerts - newser.com
Is Corvus Pharmaceuticals Inc. a candidate for recovery playJuly 2025 Sector Moves & Safe Swing Trade Setups - newser.com
Backtesting results for Corvus Pharmaceuticals Inc. trading strategiesJuly 2025 Closing Moves & Technical Pattern Recognition Alerts - newser.com
Wall Street Recap: Does Corvus Pharmaceuticals Inc meet Warren Buffetts criteriaJuly 2025 Macro Moves & Fast Gaining Stock Strategy Reports - خودرو بانک
How moving averages guide Corvus Pharmaceuticals Inc. trading2025 Big Picture & Free High Return Stock Watch Alerts - newser.com
Risk vs reward if holding onto Corvus Pharmaceuticals Inc.2025 Market Outlook & Capital Efficient Trade Techniques - newser.com
Published on: 2025-09-18 17:12:36 - newser.com
How sentiment analysis helps forecast Corvus Pharmaceuticals Inc.Portfolio Value Summary & AI Based Buy/Sell Signal Reports - newser.com
Volume Recap: Can Corvus Pharmaceuticals Inc generate free cash flowJuly 2025 Levels & Reliable Intraday Trade Plans - خودرو بانک
Corvus Pharmaceuticals Inc Stock (CRVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Corvus Pharmaceuticals Inc Stock (CRVS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Thompson Peter A. | Director |
Jun 27 '25 |
Sale |
4.16 |
1,176,332 |
4,891,894 |
7,165,006 |
| Jones William Benton | See Remarks |
Jun 04 '25 |
Option Exercise |
3.50 |
19,357 |
67,750 |
173,130 |
| MILLER RICHARD A MD | President and CEO |
May 07 '25 |
Option Exercise |
3.50 |
559,073 |
1,956,756 |
1,136,707 |
5.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):